Search This Blog

Friday, July 16, 2021

Imago BioSciences, Inc. Announces Pricing of Upsized IPO

  Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Imago, are expected to be $134.4 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock are being offered by Imago. Imago has also granted the underwriters a 30-day option to purchase from Imago up to an additional 1,260,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Imago’s common stock has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading under the symbol “IMGO” on July 16, 2021. The offering is expected to close on July 20, 2021, subject to satisfaction of customary closing conditions.

Jefferies, Cowen, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.

https://www.biospace.com/article/releases/imago-biosciences-inc-announces-pricing-of-upsized-initial-public-offering-of-common-stock-july-16-2021/

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Conference

 Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from the randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS). Results of respiratory function were highlighted at the biennial Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases conference hosted by the University of Vermont, Burlington, VT, on July 15. The invited presentation was given by Mesoblast Chief Executive Officer, Dr Silviu Itescu, and materials have been lodged with the ASX.

The trial in mechanically ventilated COVID-19 patients with moderate/severe ARDS enrolled 222 patients across the United States, of whom 217 were randomized 1:1 and received either standard of care alone or standard of care plus 2 intravenous infusions of remestemcel-L at a dose of 2 million cells/kg 3-5 days apart. As previously announced, while the trial did not meet its endpoint of 43% reduction in overall mortality, mortality was reduced through 60 days in the pre-specified subgroup analysis of 123 patients younger than 65, but not in those older than 65 where a more exuberant inflammatory response due to defective immune-mediated viral clearance mechanisms may require more prolonged or higher dosing of anti-inflammatory therapy. The mortality benefit in patients under 65 was even greater when remestemcel-L was used in addition to dexamethasone as standard of care.

https://finance.yahoo.com/news/mesoblast-presents-respiratory-function-results-001500578.html

Preclinical oncology biotech TScan Therapeutics sets terms for $100 million IPO

 TScan Therapeutics, a preclinical biotech developing engineered T cell cancer therapies, announced terms for its IPO on Monday.


The Waltham, MA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, TScan Therapeutics would command a fully diluted market value of $404 million.

TScan Therapeutics is developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of hematological and solid tumors. The company uses one of its propriety technology platforms, TargetScan, to analyze the T cells of cancer patients who have shown excellent responses to immunotherapy to inform the design of their TCR-T therapies. The company plans to submit INDs for its lead two liquid tumor candidates in the 4Q21 and at least three of its four solid tumor candidates in the 2H22.

TScan Therapeutics was founded in 2018 and booked $3 million in collaboration and license revenue for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol TCRX. Morgan Stanley, Jefferies, Cowen, and Barclays are the joint bookrunners on the deal. It is expected to price during the week of July 12, 2021.

IBIO: Success in preclinical studies for Covid vaccine

  iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (“N protein”) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response.

Data on commercially available COVID-19 vaccines - all of which target the spike protein (“S protein”) - suggests that neutralizing titers are effective, but likely to wane over time. In addition, the robustness of T-cell priming and cellular immunity achieved by S protein-directed vaccines may not be sufficient to create a durable immune response, especially in the context of emerging variant strains of the virus. In contrast, the N protein gene is more conserved and stable than the spike, with 90% amino acid homology and fewer mutations over time. Notably, the SARS-CoV-2 N protein shares substantial sequence conservation with the nucleocapsid of other coronaviruses.

It has been observed that the N protein can induce SARS-specific T-cell proliferation. The IBIO-202 immunization data are consistent with that, as a strong, cytotoxic, memory T-cell response was seen, rather than an inflammatory response. In addition, T-cell priming was achieved via both intramuscular and intranasal administration, allowing for the further exploration of multiple routes of administration and their respective benefits.

“Studies of convalescent sera from patients that have recovered from SARS-CoV-2 infection have shown that the combination of N-directed and S-directed immunity is important,” said Martin Brenner, DVM. Ph.D., iBio’s CSO. “Accordingly, we believe the N protein strategy of IBIO-202 may be complementary with existing S-directed vaccines, conferring additional protective effects that more closely mimic the natural immune responses of patients that have cleared the virus.”


Thursday, July 15, 2021

Who is most likely to develop severe COVID-19 even after a second jab?

 Older individuals with many underlying medical conditions and immunosuppression are more likely to contract coronavirus and would develop a severe case of COVID-19 even after being fully vaccinated, according to a world-first study conducted in Israel.

A minority of vaccinated individuals will contract coronavirus, and a small percentage of those will end up hospitalized because of the virus. This is called a breakthrough infection.
But who are these people?
A team of Israeli doctors led by Prof. Tal Brosh, head of the Infectious Disease Unit at Samson Assuta Ashdod Hospital, studied 152 fully vaccinated patients from 17 hospitals who developed COVID-19 more than seven days after they received their second vaccine dose and required hospitalization before the end of April.
The cohort was small because not many vaccinated people who contract coronavirus develop a severe infection, as the vaccine is 97% to 98% effective against the standard variant – and is proving to be almost as effective against the Delta variant. So far, despite a rapid spike in coronavirus cases in Israel, the number of serious cases seems to be climbing slowly.

“Overall, we can say that the main thing is that these are not healthy people,” Brosh told The Jerusalem Post in an interview. “Almost all of them (96%) had comorbidities: heart disease, lung disease, renal disease, dementia, cancer, or other common ailments. So, people who get breakthrough infections and are admitted are sicker than a usual person.”
Of those who were hospitalized, 38 had what were defined as “poor outcomes,” meaning they were mechanically ventilated or had died.
Specifically, 71% had hypertension; 48% diabetes; 27% congestive heart failure; 24% chronic kidney disease; 24% chronic lung disease; 19% dementia; and 24% cancer. Only 6% did not have any underlying medical condition.
Moreover, the study showed that 40% of patients were immunocompromised.
“If your immune system does not function well, you are at higher risk for not developing protection from vaccination,” Brosh said, adding that some 35% of patients had no detectable antibodies – meaning they had failed to mount an immune response to the vaccine.
The median time that elapsed from the second dose to hospitalization was 40 days. The median age of the patients was 71. In most cases the source of the patient’s infection was unknown.
Brosh said that although this study was conducted when the Alpha variant was active in Israel and the majority of cases had that virus strain, he said it is likely that the characteristics still apply currently – to those who are infected with the Delta variant that now accounts for more than 90% of infections in Israel.
He said that the Delta variant seems to break through the vaccine more than its Alpha predecessor, but it is still unclear if the variant causes more severe infections – despite some suggestions of this by the Health Ministry.
Still, he said there is an important message that the public should heed:
“If you are older and have comorbidities – and definitely, if you have a lot of comorbidities – or are immunocompromised, you cannot assume you will be well protected by the vaccine,” Brosh said. “When there is a lot of transmission in the community, you should take care of yourself.”

Lyft bringing back shared rides; will require everyone to wear masks

 Lyft said Thursday it’s bringing back its shared rides booking option in select U.S. markets for the first time since the pandemic.

After initially being battered by the pandemic, rideshare companies are starting to report an increase in customers. Bringing back shared rides, a cheaper option, could attract even more price-conscious customers — especially as costs have shot up due to a misbalance in driver supply and rider demand.

It’s also a sign the company is confident in Covid recovery, despite being reintroduced while only about 59% of all U.S. adults are fully vaccinated. The highly contagious Delta variant is also raising concerns about further infections.

Starting Monday, consumers in Philadelphia, Chicago and Denver can book the option that allows multiple passengers to split a car that’s going in the same direction. The company said it plans to expand to more markets in the coming months.

As part of the reintroduction, Lyft is introducing new rules meant to curb the spread of Covid-19 in its rides, including limiting the number of seats and required mask-wearing.

Here are the new rules:

  • All riders and drivers are required to wear masks.
  • Each shared ride will be limited to two riders total to help maximize physical distance (this also means that riders will not be able to book a Shared ride for two people at this time). 
  • The front and middle seats must be kept empty.
  • Eating and drinking are not allowed during the ride.
  • If anyone in the car isn’t following the above guidelines, riders and drivers have the ability to cancel the ride without penalty and report any issues to Lyft.

Uber, the company’s main rival, also pulled shared rides last March and has yet to reintroduce the option.

“We’ll explore re-launching Pool when the time is right and will follow the guidance of health experts,” a spokesperson told CNBC.

https://www.cnbc.com/2021/07/15/lyft-bringing-back-shared-rides-will-require-everyone-to-wear-masks.html

4 NFL teams remain under 50% vaccinated

 Four NFL teams remain under 50% vaccinated less than two weeks from the start of training camp, a person familiar with the vaccination rates told The Associated Press.

Washington, Indianapolis, Arizona and the Los Angeles Chargers had the four lowest COVID-19 vaccination rates in the league as of Thursday, according to the person, who spoke on condition of anonymity, because the league hasn’t released the numbers.

Pittsburgh, Miami, Carolina and Denver have the highest vaccination rates and are among 10 teams that have achieved at least 85%. About 73% of players have been vaccinated. Teams on the lower end of the vaccination table face potential competitive disadvantages.

The NFL doesn’t plan to cancel any games this season, the person said.

In a memo sent to clubs last week and obtained by the AP on Thursday, the NFL, in conjunction with the NFLPA, updated protocols to allow teams traveling to joint practices to have their daily maximum of Tier 1 and Tier 2 individuals. The traveling party will be either 100 or 140, depending on the club’s vaccination percentage. The club must limit the number of individuals traveling on the team transportation to 85 but may travel additional Tier 1 and Tier 2 staff up to the applicable daily Tier limits separately to attend the practice.

Also, beginning at the start of training camp, teams will be required to develop a method to visually identify fully vaccinated Tier 1 and Tier 2 individuals.

Utilizing color coded wristbands or credentials are recommended but clubs are free to implement other methods.

Last month, the NFL and the players’ union updated protocols to loosen restrictions for fully vaccinated players and to encourage others to get the vaccine.

Unvaccinated players must continue to get daily testing, wear masks and practice physical distancing. They won’t be allowed to eat meals with teammates, can’t participate in media or marketing activities while traveling, aren’t permitted to use the sauna or steam room and may not leave the team hotel or interact with people outside the team while traveling. Vaccinated players will not have any of those restrictions.

https://apnews.com/article/sports-football-health-coronavirus-pandemic-nfl-28b509f34f24a919750dc6c20b787c79